The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Non-Insulin Therapies For Diabetes Market Expected To Scale Between 2026 And 2030?
The non-insulin therapies for diabetes market size has experienced strong growth in recent years. It is projected to expand from $21.21 billion in 2025 to $22.59 billion in 2026, at a compound annual growth rate (CAGR) of 6.5%. This historical growth can be ascribed to a high prevalence of type 2 diabetes, a reliance on oral hypoglycemic agents, limited patient adherence to insulin therapy, an increase in hospital and retail pharmacy distribution, and the emergence of multiple drug classes.
The non-insulin therapies for diabetes market size is anticipated to undergo substantial expansion over the next few years. It is projected to climb to $28.39 billion by 2030, achieving a compound annual growth rate (CAGR) of 5.9%. This projected growth can be ascribed to a rise in the uptake of non-insulin drug combinations, the increasing application of glp-1 and sglt2 inhibitors, the broadening of online pharmacy channels, the evolving approaches of personalized and precision medicine, and the progressing integration of digital health and remote monitoring. Significant trends expected during the forecast period encompass a growing adoption of personalized diabetes management, a rise in the use of AI-driven glucose monitoring systems, an expanding integration of telemedicine-linked therapy solutions, an increasing implementation of data-driven clinical decision support, and the advancing deployment of connected devices for remote patient care.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16494&type=smp
What Key Factors Are Shaping The Non-Insulin Therapies For Diabetes Market Landscape?
The increasing occurrence of diabetes is anticipated to drive the expansion of non-insulin therapies for the diabetes market moving forward. Diabetes is a chronic health condition marked by high blood glucose levels, occurring when the body fails to produce sufficient insulin or utilize it correctly. The rise in diabetes cases stems from factors such as sedentary lifestyles, unhealthy eating habits, genetic predisposition, an aging global population, obesity, ethnicity, a lack of public awareness, limited healthcare access, and environmental elements. Non-insulin therapies for diabetes assist in managing the condition by enhancing insulin sensitivity, lowering glucose production in the liver, increasing glucose uptake by muscle cells, and improving overall glycemic control. For instance, in March 2024, the Office for Health Improvement & Disparities, a UK-based government agency, reported that the GP-recorded prevalence of type 2 diabetes among adults aged 17 and over grew to 7.0%, an increase from 6.8% in March 2023. Therefore, the growing prevalence of diabetes is a primary driver for the growth of non-insulin therapies for the diabetes market.
How Is Segmentation Applied In The Non-Insulin Therapies For Diabetes Market Segment Analysis?
The non-insulin therapies for diabetes market covered in this report is segmented –
1) By Type: Biguanides, Sulfonylureas, Thiazolidinediones (TZDs), DPP 4 Inhibitors, GLP 1 Analogs Or Agonists, SGLT2 Inhibitors
2) By Route Of Administration: Oral, Injectable
3) By Application: Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals Or Clinics, Homecare Or Patients, Other End-Users
Subsegments:
1) By Biguanides: Metformin, Combination Of Metformin With Other Drugs
2) By Sulfonylureas: Glimepiride, Glipizide, Glyburide
3) By Thiazolidinediones (TZDs): Pioglitazone, Rosiglitazone
4) By DPP 4 Inhibitors: Sitagliptin, Saxagliptin, Linagliptin
5) By GLP 1 Analogs Or Agonists: Exenatide, Liraglutide, Dulaglutide
6) By SGLT2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin
What Market Trends Are Affecting The Non-Insulin Therapies For Diabetes Market?
Leading companies in the non-insulin therapies for diabetes market are concentrating on developing advanced solutions, such as non-insulin GLP-1 receptor agonists, to broaden treatment options, improve glycemic control, and strengthen their competitive standing within the diabetes and obesity care landscape. The launch of non-insulin GLP-1 receptor agonists signifies the introduction of therapies designed to target GLP-1 receptors, aiding in blood glucose regulation and weight reduction without the need for insulin. For instance, in March 2025, Eli Lilly and Company, a US-based pharmaceutical firm specializing in diabetes and metabolic therapies, introduced Mounjaro (tirzepatide) in India after receiving approval from the Central Drugs Standard Control Organisation. Mounjaro, formulated as a dual GIP and GLP-1 receptor agonist, addresses crucial challenges in type 2 diabetes and obesity management by offering once-weekly subcutaneous administration, enhancing glycemic control, reducing appetite, slowing gastric emptying, and supporting significant weight reduction, with initial dosing options of 2.5 mg and 5 mg aimed at improving patient adherence and long-term outcomes.
Who Are The Companies Participating In The Non-Insulin Therapies For Diabetes Market Environment?
Major companies operating in the non-insulin therapies for diabetes market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi, The Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Les Servier Laboratories, Sumitomo Dainippon Pharma Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Uni-Bio Science Group Ltd., Intarcia Therapeutics, Janssen Pharmaceuticals, Boan Biotech, SatRx LLC
Get The Full Non-Insulin Therapies For Diabetes Market Report:
Which Region Is The Largest In The Non-Insulin Therapies For Diabetes Market?
North America was the largest region in the non-insulin therapies for diabetes market in 2025. The regions covered in the non-insulin therapies for diabetes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Non-Insulin Therapies For Diabetes Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Non-Insulin Therapies For Diabetes Market 2026, By The Business Research Company
Patient Transport Services Market Report 2026
https://www.thebusinessresearchcompany.com/report/patient-transport-services-global-market-report
Healthcare Transportation Service Market Report
Alternate Transportation Market Report
https://www.thebusinessresearchcompany.com/report/alternate-transportation-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model